Abbott’s Investigational MitraClip(R) System Demonstrates Strong Safety Results And Improved Clinical Outcomes For …

Published May 30, 2010

Abbott’s Investigational MitraClip(R) System Demonstrates Strong Safety Results And Improved Clinical Outcomes For …
Abbott (NYSE: ABT) today announced new data from the landmark EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) trial, which provide additional details about the safety and clinical benefit of Abbott’s investigational MitraClip® system for the two causes of mitral regurgitation (MR) – functional MR (FMR) or degenerative MR (DMR). In the EVEREST II trial, the 30-day major adverse event …